BOSTON ( TheStreet) -- The biotech sector in rewind for the week ending Oct. 8, 2010:

Sanofi-Aventis ( SNY) launched a $69-a-share hostile tender offer for Genzyme ( GENZ) after efforts failed to reach a takeover agreement with Genzyme management on more friendly terms. Then, both companies bickered over whether Sanofi offered $80-a-share, or not. Next week, the scheduling of the muay thai bout between Sanofi's Chris Viehbacher and Genzyme's Henri Termeer. My money is on Viehbacher.

ImmunoGen's ( IMGN) TDM-1 Looks Strong at ESMO

The FDA extended the review period for Salix Pharmaceuticals' ( SLXP) Xifaxan by three months to March 7, 2011. Salix is seeking to expand Xifaxan's approved label to include the treatment of non-constipation irritable bowel syndrome. The original FDA drug approval decision date was Dec. 7.

Cell Therapeutics ( CTIC) CEO Jim Bianco sold 400,000 shares of company stock at 37-38 cents a share.

This week's Biotech Stock Mailbag: Cyclacel Pharmaceuticals ( CYCC), Seattle Genetics ( SGEN), Anylam Pharmaceuticals ( ALNY), Adventrx Pharmaceuticals ( ANX), Celldex Therapeutics ( CLDX).

(Not so) fun fact: $1.7 billion in funds exited the healthcare sector in the first nine months of the year, while $15.2 billion in funds were sunk into all equity funds during the same time period, according to BioCentury. (Hat tip: ISI Group biotech analyst Mark Schoenebaum.)

The week's top-performing sector stocks: Anthera Pharmaceuticals ( ANTH) (+25.4%), Idenix Pharmaceuticals ( IDIX) (+24.8%), Neurocrine BioSciences ( NBIX) (+22.9%), Nymox Pharmaceuticals ( NYMX) (+21.9%) and Nile Therapeutics ( NLTX) (+21%).

Notable financings: Celgene ( CELG) raises $1.25 billion through a corporate bond sale; Cyclacel Pharmaceuticals nets $14 million in a private placement of stock and warrants.

Notable financing for all the wrong reasons: Spherix ( SPEX) pulls the trigger on an intraday, Rodman and Renshaw-led preferred stock and warrants sale just hours after releasing questionable phase III diabetes data.

October's FDA drug approval-palooza starts off on wrong foot with complete response letters issued to Hospira ( HSP) for the pain reliever Dyloject and Human Genome Sciences ( HGSI) for its hepatitis C drug Zalbin.

More FDA drug approval decisions coming next week: Alexa Pharmaceuticals ( ALXA) and Jazz Pharmaceuticals ( JAZZ) on Monday night, Alkermes ( ALKS) on Tuesday night.

InterMune ( ITMN) sells hepatitis C drug danoprevir to Roche, makes all-or-nothing bet on its lung drug pirfenidone.

As chief executive, David Nance drove Introgen Therapeutics into bankruptcy and disgrace, but his best pal Texas Gov. Rick Perry continues to supply Nance with taxpayer funds. The Dallas Morning News has all the illuminating details.

Onyx Pharma ( ONXX) delays multiple myeloma drug approval filing.

The week's worst-performing sector stocks: Spherix ( SPEX) (-22.6%), NuPath ( PATH) (-18.7%), SCOLR Pharma ( DDD) (-17.1%), Immucor ( BLUD) (-17.1%) and AspenBio Pharma ( APPY) (-16.9%).

Wait… I thought Pfizer ( PFE) was going to buy Generex Biotechnology ( GNBT)? Rumor mill says Pfizer reportedly interested in acquiring experimental diabetes pill from India's Biocon Ltd. (More here from @lisamjarvis.

The Wall Street Journal's Ron Winslow writes about an innovative go-fast breast cancer study design.

@adamfeuerstein's tweet of the week: Somaxon Pharmaceuticals ( SOMX)

$SOMX -- 4 weeks since the Silenor launch... Guess how many scripts have been written? C'mon, guess...

The answer is... 99 Silenor scripts! Not 99 dozen scripts. Just 99 scripts in four weeks. Ouch. $SOMX making $VNDA's Fanapt look like a rocket.

Factoid: The number of publicly traded biotech companies in the U.S. has dropped by 25% in the past three years, according to the Biotechnology Industry Organization. Me: 25%? Is that all? Should be more.

Abbott Labs ( ABT) pulled the weight-loss drug Meridia from U.S. market.

The Boston Globe sits down with newly appointed Biogen Idec ( BIIB) CEO George Scangos.

ESMO Preview: Cancer Stocks to Watch.

Readers Pick Drug Approval Winners and Losers.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Stocks

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

9 Stocks Goldman Sachs Thinks Will Blow Wall Street's Performance Away in 2019

9 Stocks Goldman Sachs Thinks Will Blow Wall Street's Performance Away in 2019

Jim Cramer on U.S.-China Trade: The Media Has it Wrong

Jim Cramer on U.S.-China Trade: The Media Has it Wrong

Is Tesla's Stock Set to Nearly Double to $500?

Is Tesla's Stock Set to Nearly Double to $500?

Tesla's $78,000 Model 3 Is a Bargain. Here's Why

Tesla's $78,000 Model 3 Is a Bargain. Here's Why